CA Cancer PI3K inhibitor J Clin 2005, 55: 242–258.Adriamycin CrossRefPubMed 23. O’Sullivan B, Shah J: New TNM staging criteria for head and neck tumors. Semin Surg Oncol 2003, 21: 30–42.CrossRefPubMed 24. Liao WT, Wang X, Xu LH, Kong QL, Yu CP, Li MZ, Shi L, Zeng MS, Song LB: Centromere protein H is a novel prognostic marker for human nonsmall cell lung cancer progression and overall patient survival. Cancer 2009, 115: 1507–1017.CrossRefPubMed
25. Jane C, Nerurkar AV, Shirsat NV, Deshpande RB, Amrapurkar AD, Karjodkar FR: Increased survivin expression in high-grade oral squamous cell carcinoma: a study in Indian tobacco chewers. J Oral Pathol Med 2006, 35: 595–601.CrossRefPubMed 26. Kops GJ, Weaver BA, Cleveland DW: On the road to cancer: aneuploidy and the mitotic checkpoint. Nat Rev Cancer 2005, 5: 773–785.CrossRefPubMed 27. de la Guardia C, Casiano CA, Trinidad-Pinedo J, Baez A: CENP-F gene amplification and overexpression in head and neck squamous cell carcinomas. Head Neck Trichostatin A nmr 2001, 23: 104–112.CrossRefPubMed 28. Clark GM, Allred DC, Hilsenbeck SG, Chamness GC, Osborne CK, Jones D, Lee WH: Mitosin (a new proliferation marker) correlates with clinical outcome in node-negative breast cancer. Cancer Res 1997, 57: 5505–5508.PubMed 29. Carvalho A,
Carmena M, Sambade C, Earnshaw WC, Wheatley SP: Survivin is required for stable checkpoint activation in taxol-treated HeLa cells. J Cell Sci 2003, 116: 2987–2998.CrossRefPubMed 30. Lens SM, Vader G, Medema RH: The case for Survivin as mitotic regulator. Curr Opin Cell Biol 2006, 18: 616–622.CrossRefPubMed 31. Altieri DC: Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 2003, 22: 8581–8589.CrossRefPubMed 32. Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC, Altieri DC: Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 1998, 396: 580–584.CrossRefPubMed 33. Lo Muzio L, Farina A, Rubini C, Pezzetti F, Stabellini G, Laino G, Santarelli A, Pannone G, Bufo P, de Lillo A, Carinci F: Survivin as prognostic factor in
squamous cell carcinoma of the oral cavity. Cancer Lett 2005, 225: 27–33.CrossRefPubMed 34. Lo Muzio L, Pannone G, Leonardi R, Staibano S, Mignogna MD, De Rosa G, Kudo Y, Takata T, Altieri DC: Survivin, a potential early predictor of tumor progression in the oral mucosa. J Dent Res 2003, 82: 923–928.CrossRefPubMed Pembrolizumab in vivo Competing interests The authors declare that they have no competing interests. Authors’ contributions WL carried out cell cultures, establishment of stable cell lines, proliferation functional assays, and preparation of manuscript. CY and DW participated in RT-PCR and immunohistochemistry, as well as data analysis. LX and GW have been involved in western blot analysis and data interpretation. LZ participated in critical revision of the manuscript. MZ participated in the study design and coordination and helped to revise the manuscript.